Intuitive Surgical Inc.
ISRG
$452.07
-2.67%
Intuitive Surgical Inc. is a leading developer and manufacturer of robotic systems for minimally invasive surgery. It is the dominant player in the robotic-assisted surgery market, with its core advantage stemming from a vast installed base of da Vinci systems and a recurring revenue model from instruments and services.…
ISRG
Intuitive Surgical Inc.
$452.07
Related headlines
Investment Opinion: Should I buy ISRG Today?
Based on a synthesis of the strong fundamentals, dominant market position, and current premium valuation, the objective assessment leans towards Hold. The stock is not a clear 'Buy' at current levels due to the high valuation multiples which leave little room for error, despite the quality of the business. It could be a candidate for accumulation on further weakness for long-term investors comfortable with its growth profile and associated risks.
Sign up to view all
ISRG 12-Month Price Forecast
The investment case is a clash between exceptional business quality and an exceptionally high price. The recent pullback has improved the risk/reward profile, but the valuation remains demanding, warranting a neutral stance with a bias towards the base case outcome.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Intuitive Surgical Inc.'s 12-month outlook, with a consensus price target around $587.69 and implied upside of +30.0% versus the current price.
Average Target
$587.69
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$362 - $588
Analyst target range
Wall Street analyst coverage for Intuitive Surgical is active, with recent institutional ratings showing a mix of 'Buy', 'Overweight', and 'Neutral' stances from firms like Citigroup, Barclays, Piper Sandler, and UBS. The provided data includes consensus estimates for future performance, with an average estimated EPS of $16.55 and average estimated revenue of $18.89 billion. However, specific consensus target price and ratings distribution data are not available in the provided inputs.
Bulls vs Bears: ISRG Investment Factors
Intuitive Surgical is a fundamentally strong company with a dominant market position and excellent financials, currently facing a significant valuation reset. The recent price correction reflects concerns over its premium valuation and a specific regulatory issue, but the underlying business remains robust with double-digit growth.
Bullish
- Dominant Market Position: Over 10,000 da Vinci systems installed globally creates a significant moat.
- Strong Recurring Revenue: High-margin instruments and services provide stable, predictable cash flow.
- Robust Financial Health: Minimal debt, high liquidity with a current ratio of 4.87.
- Solid Growth Trajectory: Q4 revenue grew 18.8% YoY, with strong profitability (27.7% net margin).
Bearish
- Extremely High Valuation: Trailing P/E of 70.8 and P/S of 20.1 price in near-perfect execution.
- Recent Regulatory Headwind: FDA safety concern over stapler creates near-term uncertainty and risk.
- Sharp Recent Price Correction: Stock down 18.6% over 3 months, underperforming S&P 500 significantly.
- Market Saturation Concerns: Growth may slow as penetration in core markets increases.
ISRG Technical Analysis
The stock has experienced significant volatility over the past six months, with a strong rally from October 2025 into early January 2026, followed by a sharp correction. The price surged from around $443 in early October to a peak near $593 in early January, representing a gain of over 30%, before declining to the current level of $460.99.
Short-term performance has been weak, with the stock down 18.60% over the last three months and 8.44% over the last month. This underperformance is notable compared to the broader market, as indicated by relative strength figures of -13.97 and -3.19 against the S&P 500 for the 3-month and 1-month periods, respectively.
The current price of $460.99 sits near the lower end of its 52-week range of $425 to $603.88, approximately 23.6% below the 52-week high. The price is also below the levels seen in late October 2025, indicating a full retracement of the late-2025 rally.
Beta
1.68
1.68x market volatility
Max Drawdown
-26.1%
Largest decline past year
52-Week Range
$425-$604
Price range past year
Annual Return
-10.8%
Cumulative gain past year
| Period | ISRG Return | S&P 500 |
|---|---|---|
| 1m | -9.1% | -3.6% |
| 3m | -19.6% | -4.0% |
| 6m | -0.1% | -2.0% |
| 1y | -10.8% | +16.2% |
| ytd | -19.6% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ISRG Fundamental Analysis
Revenue growth remains robust, with Q4 2025 revenue of $2.87 billion representing an 18.8% year-over-year increase. Profitability is strong, with a net margin of 27.7% for the quarter, and gross margins have consistently been above 65%. The quarterly net income of $794.8 million shows solid profitability.
The company maintains an exceptionally strong financial position with minimal debt, evidenced by a debt-to-equity ratio of only 0.017. Liquidity is excellent, with a current ratio of 4.87. Cash flow generation is healthy, with trailing twelve-month free cash flow of $2.49 billion.
Operational efficiency is sound, with a return on equity (ROE) of 16.0% and a return on assets (ROA) of 9.4%. The company's asset turnover, while not exceptionally high, is typical for a capital-intensive medical device manufacturer with high-margin recurring revenue streams.
Quarterly Revenue
$2.9B
2025-12
Revenue YoY Growth
+0.18%
YoY Comparison
Gross Margin
+0.66%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ISRG Overvalued?
Given the company's substantial positive net income, the primary valuation metric is the price-to-earnings (P/E) ratio. The trailing P/E ratio is 70.8, which is elevated, while the forward P/E is 40.3 based on analyst EPS estimates. The high P/E reflects the market's expectation for continued strong growth.
Other valuation metrics also appear rich, with a price-to-sales (P/S) ratio of 20.1 and an EV/EBITDA of 55.0. The price-to-book (P/B) ratio of 11.3 further indicates a premium valuation. No industry average comparison data was provided in the inputs for a direct peer assessment.
PE
70.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 49x~84x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
55.0x
Enterprise Value Multiple
Investment Risk Disclosure
The primary risk is valuation compression. With a trailing P/E of 70.8 and forward P/E of 40.3, the stock is priced for sustained high growth. Any earnings miss or growth deceleration could trigger further multiple contraction, as seen in the recent 18.6% three-month decline. The high beta of 1.68 also exposes the stock to amplified downside in a market downturn.
Operational and regulatory risks are present. The recent FDA flag regarding a safety concern with a surgical stapler highlights the constant regulatory scrutiny in the medical device industry. While the company's dominant position may help it navigate this, it poses a near-term reputational and potential financial risk. Furthermore, the business model relies on continuous system placements and procedure growth; economic pressures on hospital capital budgets could slow new system sales.
Competitive risks, while currently muted due to Intuitive's significant moat, are a long-term consideration. The high margins and large market attract potential competitors. Execution risks in expanding into new surgical specialties and geographies also exist, though the company has a strong track record.
FAQ
Key risks include: 1) Valuation compression if growth slows (high P/E of 70.8). 2) Regulatory challenges, as seen with the recent FDA safety flag. 3) Market saturation in core procedures. 4) High stock volatility (Beta 1.68). 5) Economic pressures affecting hospital capital spending for new system purchases.
The 12-month outlook is mixed with a base case target of $480-$550, representing modest upside from $461. The bull case ($580-$604) requires flawless execution, while the bear case (~$425-$460) involves growth or multiple disappointment. The consensus leans towards moderate appreciation as the company grows into its valuation, with a high probability (60%) assigned to the base case.
ISRG appears overvalued based on traditional metrics. Its trailing P/E of 70.8 and P/S ratio of 20.1 are very high, even for a growth company. The forward P/E of 40.3 is more reasonable but still implies significant future growth. The valuation is rich and suggests the market has high expectations that must be met or exceeded for the stock to advance.
ISRG is a stock for investors seeking high-quality growth, but timing is crucial. At a trailing P/E of 70.8, it is expensive. The recent 18.6% three-month decline has improved its valuation, but it remains premium. It may be suitable for long-term investors willing to tolerate volatility for exposure to a robotic surgery leader, but it is not a low-risk buy.
ISRG is predominantly a long-term investment. Its value proposition is based on the multi-decade adoption of robotic surgery, recurring revenue streams, and technological innovation. The high valuation and recent volatility make it challenging for short-term trading. Investors should have an investment horizon of 3-5 years or more to allow the underlying business growth to justify the current price.